Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU

Intensive Care Medicine

Volumn 42, Issue 6, 2016, Pages 955-958

  Bassetti, Matteo ^a   Poulakou, Garyphallia ^b   Timsit, Jean François ^c,d  

^a S Maria Hospital   (Italy)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CHLORHEXIDINE; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL TRANSMISSION; CATHETER INFECTION; COMMUNITY ACQUIRED INFECTION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISEASES; DRUG DOSE REGIMEN; DRUG MONITORING; EDITORIAL; FEEDBACK SYSTEM; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INFECTION; INFECTION RISK; INTENSIVE CARE UNIT; INTERPERSONAL COMMUNICATION; KLEBSIELLA PNEUMONIAE; LABORATORY PERSONNEL; LEADERSHIP; MEDICAL STAFF; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NEUTROPENIA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; SUPERINFECTION; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIAL INFECTIONS; DRUG EFFECTS; INFECTION CONTROL; MICROBIOLOGY; MORTALITY; STANDARDS; TRANSMISSION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; SEPSIS;

EID: 84962159240     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4341-4     Document Type: Editorial

References (21)

1. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ (2016) Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387:176–187. doi:10.1016/S0140-6736(15)00473-0
2. Carlet J (2015) Ten tips on how to win the war against resistance to antibiotics. Intensive Care Med 41:899–901. doi:10.1007/s00134-014-3594-z
3. Bretonnière C, Leone M, Milési C, Allaouchiche B, Armand-Lefevre L, Baldesi O, Bouadma L, Decré D, Figueiredo S, Gauzit R et al (2015) Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med 41:1181–1196. doi:10.1007/s00134-015-3853-7
4. Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, Riccio LM, Popovsky KA, Sawyer RG (2012) Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis 12:774–780. doi:10.1016/S1473-3099(12)70151-2
5. Garnacho-Montero J, Dimopoulos G, Poulakou G, Akova M, Cisneros JM, De Waele J, Petrosillo N, Seifert H, Timsit JF, Vila J et al (2015) Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med 41:2057–2075. doi:10.1007/s00134-015-4079-4
6. Mimoz O, Lucet JC, Kerforne T, Pascal J, Souweine B, Goudet V, Mercat A, Bouadma L, Lasocki S, Alfandari S et al (2015) Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet 386:2069–2077. doi:10.1016/S0140-6736(15)00244-5
7. Noto MJ, Wheeler AP (2015) Understanding chlorhexidine decolonization strategies. Intensive Care Med 41:1351–1354. doi:10.1007/s00134-015-3846-6
8. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776–795. doi:10.1007/s00134-015-3719-z
9. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S et al (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133–2143. doi:10.1093/jac/dkv086
10. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J et al (2014) Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340–1351. doi:10.1007/s00134-014-3403-8
11. Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE et al (2016) Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomized controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. doi:10.1007/s00134-015-4188-0
12. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL (2015) A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med 192:1298–1305. doi:10.1164/rccm.201505-0857OC
13. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P et al (2014) DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083. doi:10.1093/cid/ciu027
14. De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-Roels I, Hoste E, Depuydt P, Decruyenaere J et al (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40:380–387. doi:10.1007/s00134-013-3187-2
15. de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R (2014) Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 40:998–1005. doi:10.1007/s00134-014-3276-x
16. Montravers P, Dupont H, Bedos JP, Bret P, Tigecycline Group (2014) Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med 40:988–997. doi:10.1007/s00134-014-3323-7
17. De Pascale G, Fortuna S, Tumbarello M, Cutuli SL, Vallecoccia M, Spanu T, Bello G, Montini L, Pennisi MA, Navarra P et al (2015) Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med 41:103–110. doi:10.1007/s00134-014-3550-y
18. Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, Tacey M, Timsit JF, Leone M, Zahar JR et al (2016) A systematic review of the definitions, determinants and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis 62(8):1009–17
19. Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, Ortiz-Leyba C, Márquez-Vácaro JA (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40. doi:10.1007/s00134-013-3077-7
20. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanèse J, Jaber S, Lepape A, Constantin JM, Papazian L, Bruder N, Allaouchiche B et al (2014) De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40:1399–1408. doi:10.1007/s00134-014-3411-8
21. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. doi:10.1016/S1473-3099(16)00053-0